Results 251 to 260 of about 1,394,594 (296)

Nonpeptide angiotensin II receptor antagonists

Trends in Pharmacological Sciences, 1991
Substantial progress has been made recently in the development of nonpeptide angiotensin II receptor antagonists, a goal that has long remained an unmet challenge. Pieter Timmermans and colleagues review the pharmacology and the course of events that led to the identification of the lead compound and clinical candidate DuP753. Nonpeptide angiotensin II
P B, Timmermans, P C, Wong, A T, Chiu, W F, Herblin   +3 more
openaire   +2 more sources

Angiotensin II Receptor Antagonists

High Blood Pressure & Cardiovascular Prevention, 2007
Stroke is a devastating disease that heavily affects overall cardiovascular mortality and quality of life in surviving patients, and has a relevant burden on healthcare systems. Recent data derived both from large epidemiological surveys and from the analysis of events occurring in the clinical trials on hypertension, performed over the last 10 years ...
Giuliano Tocci, Francesca Giovannelli, Caterina Facciolo   +2 more
openaire   +1 more source

Angiotensin receptor antagonists

Abstract The renin–angiotensin–aldosterone system (RAAS) is activated in patients with heart failure and contributes to many of the detrimental effects seen in these patients. Antagonists to the angiotensin II type-1 (AT1)-receptor (ARBs) provide a pharmacologically different mechanism of inhibiting the RAAS to ACE inhibitors.
Roy S. Gardner, Theresa A. McDonagh, Daniel J. Doherty, Nikki L. Walker   +3 more
openaire   +1 more source

Angiotensin Receptor Antagonists and Cardiovascular Remodeling

1998
Angiotensin (Ang) II is one of the key hormones involved in cardiovascular homeostasis. It has potent vasoconstrictor effects and is directly involved in the vascular and cardiac remodeling observed in response to chronic or acute hypertension. Two major Ang II receptor subtypes, AT1 and AT2, have been described, and their roles in vivo and in vitro ...
Sabri, K., Chassagne, Catherine, Lévy, B., Samuel, J.L., Rappaport, L.   +4 more
openaire   +1 more source

Angiotensin receptor antagonists.

Australian family physician, 2000
Angiotensin receptor antagonists are a relatively new class of cardiovascular drugs for which the clinical application has not yet been completely defined.This article reviews the pharmacology of the various angiotensin receptor antagonists available in Australia, including their mode of action, side effects and potential drug interactions.Angiotensin ...
W, Wong, L, Howes
openaire   +1 more source

Angiotensin II receptors and angiotensin II receptor antagonists.

Pharmacological Reviews, 1993
P B, Timmermans, P C, Wong, A T, Chiu, W F, Herblin, P, Benfield, D J, Carini, R J, Lee, R R, Wexler, J A, Saye, R D, Smith   +9 more
openaire   +2 more sources

Angiotensin receptor antagonists as a treatment for hypertension

Journal of Hypertension, 1994
R J, MacFadyen, J L, Reid
openaire   +2 more sources

Angiotensin receptor antagonists

The Lancet, 1997
openaire   +2 more sources

Angiotensin II receptor antagonists.

Arzneimittel-Forschung, 1993
The development of novel non-peptide compounds with high affinity for-angiotensin II (Ang II) receptors has greatly facilitated the subclassification of Ang II receptors into AT1- and AT2-receptor subtypes. Whereas PD 123177 (1-(4-amino-3-methylphenyl)methyl-5-diphenyl-acetyl-4,5,6,7-tetrahydro- 1H-imidazol [4,5-c]pyridine-6-carboxylic acid) is the ...
J C, van Meel, M, Entzeroth, N, Hauel, B, Narr, U, Ries, W, Wienen   +5 more
openaire   +1 more source

Angiotensin receptor antagonists

Reactions Weekly, 2008
openaire   +1 more source